Why Alnylam Pharmaceuticals, Inc. (ALNY) stock moved
Alnylam Pharmaceuticals, Inc. (ALNY) shares fell 0.6% to $219.00 as of August 4, 2026, a slight decline from the prior close of $220.33. BestStocks flagged the session as a major change for ALNY. Below, we break down what changed for ALNY, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
ALNY fell 0.6% to $219.00
ALNY fell 0.6% in its latest session, moving from $220.33 to $219.00.
What it means for Alnylam Pharmaceuticals, Inc. investors
For Alnylam Pharmaceuticals, Inc. investors, the recent signals add up to a strong bearish shift. On the constructive side: ALNY moved +0.59% from $321.59 to $323.50 on 2026-07-08. Weighing against that: Earnings missed expectations; Negative session, down 0.6%. Wall Street's consensus price target sits at $387.18, implying +76.8% upside from $219.00. BestStocks rates the overall signal quality low (48/100). With earnings roughly 86 days out, the next report is the most likely near-term test of the move.
ALNY price reaction
ALNY last traded at $219.00, down $1.33 (-0.60%) from the previous close of $220.33. The session traded on 2.4× average volume (very high), so the move carried above-average conviction. Over the past month the stock has ranged between $205.48 and $323.50, and it currently sits about 11% of the way up that band.
Bullish and bearish analyst opinions on Alnylam Pharmaceuticals, Inc. (ALNY)
The consensus analyst price target on Alnylam Pharmaceuticals, Inc. (ALNY) is $387.18, 76.8% above the recent $219.00. Over the past 90 days analysts logged 0 upgrades, 15 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ALNY line up.
The bullish case
- Wall Street's consensus price target of $387.18 implies +76.8% upside from $219.00.
- The Street's most bullish target is $455.00 (+107.8%).
- ALNY moved +0.59% from $321.59 to $323.50 on 2026-07-08.
The bearish case
- Earnings missed expectations.
- Negative session, down 0.6%.
- High volume 2.4x on decline — distribution signal.
- Alnylam Pharmaceuticals plummeted 27.66% to $207.34 following an earnings report and material event filing (8-K) released today.
Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 4, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for ALNY
Frequently asked questions about ALNY
Why did Alnylam Pharmaceuticals, Inc. (ALNY) stock move?
ALNY fell 0.6% to $219.00. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did ALNY stock fall?
ALNY lost 0.60% ($1.33) versus the prior close of $220.33, last trading at $219.00 on 2.4× average volume.
When is Alnylam Pharmaceuticals, Inc.'s next earnings date?
ALNY's next earnings report is estimated for 2026-10-29 — about 86 days away.
What is the analyst price target for ALNY?
The consensus analyst price target for ALNY is $387.18, about 76.8% above the current $219.00. Over the past 90 days, analysts recorded 0 upgrades, 15 maintains, and 0 downgrades.
How BestStocks tracks ALNY
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared ALNY-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for ALNY, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 4, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.